Analyst Reco. Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Real-time Estimate Cboe BZX Other stock markets 15:19:00 29/04/2024 BST			5-day change	1st Jan Change
15.78 ^USD	+2.27%		-2.06%	-27.03%

04-09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
04-03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	04-09	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	04-03	MT
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	02-28	MT
Citigroup Initiates Denali Therapeutics With Buy Rating, Price Target is $32	12-13	MT
B. Riley Initiates Denali Therapeutics at Buy With $38 Price Target	06/09/23	MT
Wedbush Lowers Denali Therapeutics' Price Target to $31 From $37 Following Pipeline Updates, Keeps Outperform Rating	09/08/23	MT
Oppenheimer Adjusts Denali Therapeutics Price Target to $68 From $70, Maintains Outperform Rating	06/06/23	MT
Wedbush Trims Denali Therapeutics' Price Target to $37 From $38, Notes Slightly Higher Share Count; Keeps Outperform Rating	09/05/23	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $63 From $61, Maintains Overweight Rating	12/04/23	MT
Oppenheimer Adjusts Denali Therapeutics' Price Target to $70 From $85, Maintains Outperform Rating	02/03/23	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $61 From $65, Maintains Overweight Rating	01/03/23	MT
Evercore ISI Adjusts Price Target on Denali Therapeutics to $50 From $80, Maintains Outperform Rating	28/02/23	MT
Wedbush Lowers Denali Therapeutics' PT to $38 From $46, Keeps Outperform Rating	28/02/23	MT
SVB Securities Initiates Denali Therapeutics at Outperform With $50 Price Target	30/01/23	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $65 From $60, Maintains Overweight Rating	25/01/23	MT
Cowen Initiates Denali Therapeutics With Outperform Rating	05/12/22	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $60 From $67, Maintains Overweight Rating	08/11/22	MT
Berenberg Bank Adjusts Denali Therapeutics Price Target to $50 From $39, Maintains Buy Rating	08/11/22	MT
Wedbush Lowers Denali Therapeutics' Price Target to $46 From $48 on Increased Dilution, Keeps Outperform Rating	04/11/22	MT
BofA Securities Initiates Denali Therapeutics at Buy With $40 Price Target	02/11/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Analyst Reco.

Filters